On Sunday, the U.S. Food and Drug Administration (FDA) published data reporting that there were 72 total seafood entry line refusals in June, of which 2 (2.7%) were of shrimp for reasons related to banned antibiotics. Of the remaining 70 seafood entry lines refused in March, 12 were of shrimp from India found to be contaminated with salmonella or be filthy (or both) and 9 were of shrimp from Thailand found by the FDA to be filthy. Entry lines of Indian shrimp were refused from four different exporters (Kader Exports; Sagar Grandhi; Magnum Seafood; and Sai Marine Exports), while all entry lines of Thai shrimp that were refused originated from Sea Tech Intertrade Co. Ltd.
Through the first half of this year, the FDA has now refused a total of 43 entry lines of antibiotic-contaminated shrimp.
The two shrimp entry lines refused in June for reasons related to antibiotics were for shipments from Bangladesh and China:
- Rupsha Fish & Allied Industries Ltd. (Factory) (Bangladesh), a company that is currently listed twice on Import Alert 16-129 (“Detention Without Physical Examination of Seafood Products Due to Nitrofurans”) as of February 5, 2021, had one entry line refused for shrimp contaminated with nitrofurans and veterinary drug residues by the Division of West Coast Imports on June 10, 2021; and
- Dalian Zhuohong Marine Product Co., Ltd. (China), a company that is not on the green list of Import Alert 16-131 (“Detention Without Physical Examination of Aquacultured, Shrimp, Dace, and Eel from China – Presence of New Animal Drugs and/or Unsafe Food Additives”), had one entry line refused for shrimp contaminated with veterinary drug residues and unsafe additives by the Division of Northeast Imports on June 14, 2021.